Milatuzumab Stocks List
|2019-08-16||IMMU||Crossed Above 20 DMA||Bullish|
|2019-08-16||IMMU||Non-ADX 1,2,3,4 Bullish||Bullish Swing Setup|
|2019-08-16||IMMU||180 Bullish Setup||Bullish Swing Setup|
|2019-08-16||STRO||Lower Bollinger Band Walk||Weakness|
Milatuzumab (or hLL1) is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin’s lymphoma and chronic lymphocytic leukemia.The drug is the first anti-CD74 antibody that has entered into human testing and is currently being studied for the treatment of multiple myeloma. Milatuzumab has received orphan drug designation from the Food and Drug Administration in the United States for the treatment of multiple myeloma and chronic lymphocytic leukemia.
Milatuzumab was developed by Immunomedics, Inc, (Morris Plains NJ USA).